Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

820
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
820
Neural Regulation01:37

Neural Regulation

40.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.5K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

440
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
440
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

736
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
736

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The economic burden of dementia in Europe: COIN-Eu dementia.

Journal of Alzheimer's disease : JAD·2026
Same author

Neurosarcoidosis as an elusive mimicker of infection and neoplasia: a case report.

Journal of neurology·2026
Same author

Spatiotemporal deep learning for early detection of isolated REM sleep behavior disorder and Parkinson's disease using functional MRI data.

NPJ Parkinson's disease·2026
Same author

Subcutaneous natalizumab administration in relapsing-remitting multiple sclerosis: results of EASIER 2 study.

Journal of neurology·2026
Same author

Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteria.

Nature medicine·2026
Same author

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Related Experiment Video

Updated: Oct 12, 2025

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases
09:33

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases

Published on: July 28, 2013

28.6K

Longitudinal White Matter Damage Evolution in Parkinson's Disease.

Pietro Giuseppe Scamarcia1,2, Federica Agosta1,2,3, Edoardo Gioele Spinelli1,2,3

  • 1Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Movement Disorders : Official Journal of the Movement Disorder Society
|November 22, 2021
PubMed
Summary

White matter hyperintensities (WMHs) are linked to cognitive decline in Parkinson's disease (PD). Cerebral white matter microstructural damage does not significantly impact PD progression, but WMHs can predict cognitive impairment development.

Keywords:
MRIParkinson's diseaselongitudinal studynormal-appearing white matterwhite matter hyperintensity

More Related Videos

3D Modeling of the Lateral Ventricles and Histological Characterization of Periventricular Tissue in Humans and Mouse
15:26

3D Modeling of the Lateral Ventricles and Histological Characterization of Periventricular Tissue in Humans and Mouse

Published on: May 19, 2015

14.3K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.6K

Related Experiment Videos

Last Updated: Oct 12, 2025

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases
09:33

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases

Published on: July 28, 2013

28.6K
3D Modeling of the Lateral Ventricles and Histological Characterization of Periventricular Tissue in Humans and Mouse
15:26

3D Modeling of the Lateral Ventricles and Histological Characterization of Periventricular Tissue in Humans and Mouse

Published on: May 19, 2015

14.3K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.6K

Area of Science:

  • Neuroimaging
  • Neurology
  • Gerontology

Background:

  • White matter hyperintensities (WMHs) are implicated in cognitive decline during normal aging.
  • The specific role of WMHs and white matter (WM) microstructural integrity in Parkinson's disease (PD) progression remains debated.

Purpose of the Study:

  • To examine the long-term changes in cerebral white matter (WM) structure.
  • To investigate the relationship between WM alterations and clinical progression in PD patients.

Main Methods:

  • 154 PD patients and 60 controls underwent annual MRI scans and clinical/cognitive assessments for up to 4 years.
  • Tract-based spatial statistics analyzed diffusion tensor (DT) MRI metrics in WM and normal-appearing white matter (NAWM).
  • Linear mixed-effects models and regression analyses assessed longitudinal changes and risk factors for disease progression.

Main Results:

  • PD patients exhibited baseline alterations in DT MRI measures compared to controls.
  • WMH volume increased over time and correlated with cognitive impairments (global, executive, language).
  • Baseline WMH volume moderately predicted progression to mild cognitive impairment.

Conclusions:

  • WMHs are associated with cognitive decline in PD patients.
  • Cerebral white matter microstructural damage has minimal impact on clinical PD progression.
  • MRI-assessed WMHs serve as a valuable tool for monitoring cognitive impairment development in PD.